Improved understanding of underlying mechanisms, enhanced pharmacovigilance and thorough assessment of risk factors prior to drug- administration are essential to mitigate risks. Clinicians should maintain a high index of suspicion for pneumonitis in patients receiving ICIs or TKIs, and suspected cases should be promptly referred to specialized centers with expertise in therapy-related pulmonary complications.
Komninos et al. (Fri,) studied this question.